Loading…
Bioventus Inc. is projected to rise to $15.73 by 2027, a +32% move from its current price of $11.88. BVS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $11.49 | $11.88 | $12.29 | +0.02% |
| Jul 14 | $11.34 | $11.89 | $12.46 | +0.05% |
| Jul 15 | $11.22 | $11.89 | $12.60 | +0.07% |
| Jul 16 | $11.12 | $11.89 | $12.71 | +0.09% |
| Jul 17 | $11.04 | $11.89 | $12.82 | +0.11% |
| Jul 18 | $10.96 | $11.90 | $12.91 | +0.14% |
| Jul 19 | $10.89 | $11.90 | $13.00 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.89 | $11.90 | $13.00 | +0.16% |
| Week 2 | $10.51 | $11.92 | $13.51 | +0.32% |
| Week 3 | $10.24 | $11.94 | $13.92 | +0.48% |
| Week 4 | $10.01 | $11.96 | $14.27 | +0.64% |
| Week 5 | $9.82 | $11.98 | $14.60 | +0.80% |
| Week 6 | $9.65 | $11.99 | $14.90 | +0.96% |
| Week 7 | $9.50 | $12.01 | $15.19 | +1.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bioventus Inc. is a medical device company focused on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; Stimrouter to treat chronic peripheral pain, and TalisMann to provide stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products.
Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc.
was founded in 2011 and is headquartered in Durham, North Carolina.
Bioventus Inc. trades at current price $11.78 with a market cap of $798.07M and is ranked 2683. The near-term forecast for 2026 shows an average price of $11.78, a range from $7.21 to $17.37, and a neutral sentiment.
Longer-term forecasts indicate bullish sentiment and upside: 2030 average price $23.41 with ROI 98.7, and 2050 average price $177.93 with ROI 1410.4. The forecast also shows 2040 average price $92.23 with ROI 682.9. These figures illustrate potential gains and are estimates, not guarantees.
A major floor 46.2% below — a decisive break under it would weaken the trend.
The nearest floor, 33.2% below — buyers have tended to step in here.
Price is pressing into resistance (2.9% away) — a breakout level to watch.
A major ceiling 26.0% above — clearing it would confirm fresh momentum.
Key BVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.90 | Sell | $11.69 | Buy |
| MA 10 | $10.88 | Buy | $11.09 | Buy |
| MA 20 | $9.89 | Buy | $10.39 | Buy |
| MA 50 | $9.76 | Buy | $9.81 | Buy |
| MA 100 | $9.45 | Buy | $9.38 | Buy |
| MA 200 | $8.42 | Buy | $8.84 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.85 | Neutral |
| Stoch RSI (14) | 80.28 | Sell |
| CCI (20) | 124.95 | Buy |
| Williams %R (14) | -9.91 | Info |
| MACD (12,26,9) | 0.32 | Buy |
| ROC (12) | 27.88 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 90.09 | Sell |
| TRIX (15) | 0.56 | Buy |
| Awesome (5,34) | 2.44 | Buy |
| Ultimate (7,14,28) | 80.57 | Sell |
| Momentum (10) | 2.15 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 12.56 | Sell |
| ADX (14) | 27.11 | Buy |
| ATR (14) | 0.33 | Info |
The 30-day technical picture is bullish with RSI14 at 80, indicating strong momentum. The stock trades above the SMA50 of $9.61 and the SMA200 of $8.32, signaling upside potential. Support is at $7.93 and resistance at $11.78, with a 30-day price range from $9.35 to $14.85. Annualized volatility is 70.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.21 | $11.88 | $17.35 | 0% | Neutral | |
| $12.26 | $15.73 | $21.50 | +32% | Bullish | |
| $14.17 | $18.83 | $26.90 | +58% | Bullish | |
| $14.17 | $19.38 | $28.65 | +63% | Bullish | |
| $16.65 | $23.38 | $35.57 | +97% | Bullish | |
| $20.93 | $30.11 | $46.95 | +153% | Bullish | |
| $23.66 | $34.79 | $55.47 | +193% | Bullish | |
| $29.11 | $43.73 | $71.13 | +268% | Bullish | |
| $32.20 | $49.34 | $81.75 | +315% | Bullish | |
| $31.41 | $49.06 | $82.69 | +313% | Bullish | |
| $53.69 | $91.64 | $165.83 | +671% | Bullish | |
| $88.42 | $176.65 | $354.11 | +13.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.21 | $11.88 | $14.54 | +0.00% |
| August 2026 | $10.15 | $12.05 | $14.75 | +1.47% |
| September 2026 | $10.13 | $12.13 | $15.04 | +0.62% |
| October 2026 | $10.71 | $12.92 | $16.21 | +6.52% |
| November 2026 | $11.13 | $13.52 | $17.12 | +4.61% |
| December 2026 | $11.12 | $13.58 | $17.35 | +0.50% |
Click any year to see its month-by-month BVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BVS could reach as high as $17.35, with a base case around $11.88 and support toward $7.21 — roughly 0% from $11.88. Price action looks broadly range-bound.
Expect BVS to range from $12.26 to $21.50 through 2027. The $15.73 average target implies a +32% move from current prices. That is up +32% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The BVS price prediction for 2028 points to an average of $18.83 (low $14.17, high $26.90) — a potential gain of +58% on today's $11.88. Momentum favours further upside here.
In 2029, BVS is projected to trade between $14.17 and $28.65, averaging $19.38 — a potential gain of +63% from today's $11.88. That is up +3% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Bioventus Inc.'s 2030 outlook centres on $23.38, within a $16.65 to $35.57 range. That is up +21% on the projected 2029 average. That marks a +97% change versus current levels. Momentum favours further upside here.
By 2031, BVS could reach as high as $46.95, with a base case around $30.11 and support toward $20.93 — roughly +153% from $11.88. Buyers look set to stay in control over this stretch.
Expect BVS to range from $23.66 to $55.47 through 2032. The $34.79 average target implies a +193% move from current prices. That is up +16% on the projected 2031 average. Momentum favours further upside here.
The BVS price prediction for 2033 points to an average of $43.73 (low $29.11, high $71.13) — a potential gain of +268% on today's $11.88. Buyers look set to stay in control over this stretch.
In 2034, BVS is projected to trade between $32.20 and $81.75, averaging $49.34 — a potential gain of +315% from today's $11.88. That is up +13% on the projected 2033 average. Momentum favours further upside here.
Bioventus Inc.'s 2035 outlook centres on $49.06, within a $31.41 to $82.69 range. That is -1% versus the projected 2034 average. That marks a +313% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, BVS could reach as high as $165.83, with a base case around $91.64 and support toward $53.69 — roughly +671% from $11.88. Momentum favours further upside here.
Expect BVS to range from $88.42 to $354.11 through 2050. The $176.65 average target implies a +13.9x move from current prices. That is up +93% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BVS today (≈ 84.175084 BVS) could be worth
$14,869.82
+$13,869.82 (+1387%) by 2050 · US Dollar
Based on the average projected BVS price of $176.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BVSwould be worth at today's price.
$1,000 invested in BVS on Jul 10, 2025 (≈ 135.318 BVS) would be worth
$1,607.58
+$607.58 (+60.8%) today · 1.61× · US Dollar
Based on a BVS entry price of $7.39 vs. today's $11.88.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.48 | $1,133.59 | +13.4% |
| 1 month ago | $9.05 | $1,312.71 | +31.3% |
| 3 months ago | $9.06 | $1,311.26 | +31.1% |
| 6 months ago | $7.75 | $1,532.9 | +53.3% |
| 1 year ago | $7.39 | $1,607.58 | +60.8% |
| All time (5.0y) ago | $16.49 | $720.44 | -28.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BVS forecast.
Our base-case forecast reaches $24.00 around 2031.
Implied market cap at $24.00: $1.63B
In the multi-year forecast, 2026 shows average price $11.78 with min $7.21 and max $17.37; sentiment NEUTRAL. From 2027 onward, sentiment is BULLISH with rising averages, for example 2027 avg $15.70 (ROI 33.3), 2030 avg $23.41 (ROI 98.7), 2040 avg $92.23 (ROI 682.9), and 2050 avg $177.93 (ROI 1410.4). These figures highlight strong upside potential over the next couple of decades, but are estimates and not guarantees.
Tap a question to reveal the answer.
2030 Avg $23.41; min $16.49; max $36.02; ROI 98.7; sentiment BULLISH.
Forecasts show BULLISH sentiment from 2027 onward with rising averages and ROI. For example, 2027 Avg $15.70 (ROI 33.3), 2030 Avg $23.41 (ROI 98.7), and 2050 Avg $177.93 (ROI 1410.4).
The forecast shows 2040 Avg $92.23 and 2050 Avg $177.93, which implies potential to exceed $100 in the long term, but these are estimates, not guarantees.
Current price $11.78; Market cap $798.07M; Rank 2683.
Sentiment BULLISH; RSI14 80; SMA50 $9.61; SMA200 $8.32; 30-day range $9.35-$14.85; support $7.93; resistance $11.78; annualized volatility 70.
Bioventus Inc. Community Discussion
0Share your Bioventus Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.